Curated News
By: NewsRamp Editorial Staff
October 29, 2026
Regentis Biomaterials' GelrinC Shows Promise in Cartilage Repair
TLDR
- Regentis Biomaterials targets a 470,000-case U.S. knee cartilage market with GelrinC, which showed 100% greater pain improvement than microfracture.
- GelrinC is a cell-free hydrogel implant that resorbs over six to nine months, enabling controlled cartilage regeneration with a mean MOCART score of 88.8.
- Regentis Biomaterials advances GelrinC to provide lasting pain relief and mobility improvements for patients with knee cartilage damage.
- GelrinC, an off-the-shelf hydrogel implant from Regentis Biomaterials, has earned a CE mark in Europe and is advancing through U.S. Phase III trials.
Impact - Why it Matters
The development of GelrinC could revolutionize cartilage repair by offering a minimally invasive, off-the-shelf solution that potentially eliminates the need for more invasive procedures like microfracture. With its CE mark in Europe and ongoing Phase III trials in the U.S., Regentis is positioning itself to address a significant unmet need in orthopedic medicine, where durable cartilage repair remains a challenge. If approved, GelrinC could provide patients with long-lasting pain relief and improved mobility, reducing the burden on healthcare systems and improving quality of life for millions.
Summary
Regentis Biomaterials (NYSE American: RGNT) is making strides in regenerative cartilage repair with its lead product GelrinC, a cell-free, off-the-shelf hydrogel implant designed to regenerate knee cartilage. The implant gradually resorbs over six to nine months as new tissue fills the treated area. According to Regentis, its Pilot/Phase II study demonstrated 100% greater pain improvement compared to traditional microfracture treatment, and 24-month follow-up results showed a mean MOCART score of 88.8 out of 100, an MRI-based measure of cartilage repair quality. GelrinC has received a CE mark in Europe, allowing commercialization there, while the company advances its pivotal Phase III clinical study in the United States and prepares for the FDA’s Premarket Approval process. Regentis is also working to complete enrollment in its U.S. study and expand commercialization efforts, focusing on cartilage repair solutions that deliver lasting improvements in pain and mobility. For more details, visit https://ibn.fm/cTSlo.
Regentis Biomaterials is a regenerative medicine company dedicated to developing innovative tissue repair solutions. Its Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue, including inflamed cartilage and bone. GelrinC aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no off-the-shelf treatment is available. The latest news and updates relating to RGNT are available in the company’s newsroom at https//ibn.fm/RGNT.
This content has been disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement. BioMedWire (“BMW”) is a specialized communications platform focused on the Biotechnology (BioTech), Biomedical Sciences (BioMed), and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN, and a full array of tailored corporate communications solutions.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Biomaterials' GelrinC Shows Promise in Cartilage Repair
